Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 281.52% and Operating profit at -25.62% over the last 5 years
2
The company has declared Negative results for the last 5 consecutive quarters
3
With ROE of 0.29%, it has a very expensive valuation with a 8.45 Price to Book Value
4
Market Beating Performance
Stock DNA
Pharmaceuticals & Biotechnology
CNY 9,877 Million (Large Cap)
2,881.00
NA
0.00%
-0.33
1.04%
6.76
Revenue and Profits:
Net Sales:
83 Million
(Quarterly Results - Sep 2025)
Net Profit:
13 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
3.72%
0%
3.72%
6 Months
-24.82%
0%
-24.82%
1 Year
48.85%
0%
48.85%
2 Years
49.27%
0%
49.27%
3 Years
-13.61%
0%
-13.61%
4 Years
114.81%
0%
114.81%
5 Years
0%
0%
0.0%
Shanghai Yizhong Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
281.52%
EBIT Growth (5y)
-25.62%
EBIT to Interest (avg)
80.83
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.43
Sales to Capital Employed (avg)
0.19
Tax Ratio
39.09%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
32.26%
ROE (avg)
7.02%
Valuation key factors
Factor
Value
P/E Ratio
2881
Industry P/E
Price to Book Value
8.45
EV to EBIT
-984.95
EV to EBITDA
11664.53
EV to Capital Employed
13.23
EV to Sales
55.32
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-1.34%
ROE (Latest)
0.29%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
82.80
89.30
-7.28%
Operating Profit (PBDIT) excl Other Income
4.10
22.40
-81.70%
Interest
0.00
0.00
Exceptional Items
0.90
0.00
Consolidate Net Profit
12.70
23.80
-46.64%
Operating Profit Margin (Excl OI)
48.90%
213.80%
-16.49%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is -7.28% vs 25.77% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is -46.64% vs 67.61% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
172.50
359.00
-51.95%
Operating Profit (PBDIT) excl Other Income
-4.10
167.70
-102.44%
Interest
0.80
0.30
166.67%
Exceptional Items
2.80
0.40
600.00%
Consolidate Net Profit
7.00
161.60
-95.67%
Operating Profit Margin (Excl OI)
-92.80%
444.50%
-53.73%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -51.95% vs 52.64% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -95.67% vs 13.09% in Dec 2023
About Shanghai Yizhong Pharmaceutical Co., Ltd. 
Shanghai Yizhong Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






